Anzeige
Novara — A Smarter Way to Access Global Markets
Markets-Desk·im Tagesverlauf aktualisiert

Märkte

Jefferies upgrades EU utilities with RWE, E.ON, EDP as power prices rise
AktienArtikel

Jefferies upgrades EU utilities with RWE, E.ON, EDP as power prices rise

Brokerage names RWE as top power pick, E.ON as top regulated utility, and EDP as top integrated utility amid surging European power prices and regulatory tailwinds.

2 Sept 2026
Credit Exchange CEO on scaling Swiss mortgage platform to $6 bln
AktienArtikel

Credit Exchange CEO on scaling Swiss mortgage platform to $6 bln

Serkan Mirza discusses leading the Credit Exchange’s rapid growth, integrating AI and expanding into pensions as the B2B platform reshapes Switzerland’s mortgage market.

Morgan Stanley lifts ratings on Coloplast, Demant in European MedTech
AktienArtikel

Morgan Stanley lifts ratings on Coloplast, Demant in European MedTech

Analysts raise targets on hearing-aid names and rebalance coverage after strategic updates, while downgrading Smith & Nephew to equal weight. Sector remains in-line.

DAX inclusion shows mixed long-term stock performance gains
AktienArtikel

DAX inclusion shows mixed long-term stock performance gains

Deutsche Bank analysis finds new DAX entrants underperform the index by a median 8% in their first year, despite short-term liquidity boosts. Changes effective September 21.

Swiss stocks slip as oil, rate fears weigh on markets
AktienArtikel

Swiss stocks slip as oil, rate fears weigh on markets

SMI falls 0.4% as Brent crude tops $95, inflation and ECB/Fed policy expectations drive defensive rotation; Roche, Swiss Life gain while Amrize, Holcim lag.

Nvidia lifts US tech as Salesforce jumps; SMI hits session low
AktienArtikel

Nvidia lifts US tech as Salesforce jumps; SMI hits session low

Nvidia surged 8% premarket after strong outlook, lifting the Nasdaq 100, while Salesforce rallied 10% on AI-driven growth guidance. Swiss equities fell 1.2% as heavyweights weighed.

Swiss equities slip as oil, inflation and rate fears weigh
AktienArtikel

Swiss equities slip as oil, inflation and rate fears weigh

SMI falls 0.4% to 14,280 as defensive shares lag; Amrize drops 2.7% after BofA downgrade, Roche and Swiss Life advance. Brent crude tops $95/bbl after U.S.-Iran strikes.

US stocks slip at week open as oil spikes, geopolitics weigh
AktienArtikel

US stocks slip at week open as oil spikes, geopolitics weigh

Dow Jones falls 0.4% as Brent crude tops $91; Aon shares drop on $17bn KKR deal; GameStop warns on Q2 revenue amid store closures.

Swiss stocks fall as oil surge fuels inflation concerns; UBS upgrades Comet, VAT, Inficon
AktienArtikel

Swiss stocks fall as oil surge fuels inflation concerns; UBS upgrades Comet, VAT, Inficon

SMI drops 0.1% as Brent crude tops $95 a barrel after U.S.-Iran tensions escalate; UBS lifts targets on Swiss tech names. Nestlé to sell vitamins unit for $1 billion.

Swiss stocks slip as oil surges, geopolitical risks weigh on markets
AktienArtikel

Swiss stocks slip as oil surges, geopolitical risks weigh on markets

The SMI fell 0.1% to 14,323 as Brent crude topped $95 a barrel amid U.S.-Iran tensions. Tech shares led gainers, while Amrize and Partners Group lagged.

Nvidia’s strong results lift Swiss chip suppliers modestly amid mixed market signals
AktienArtikel

Nvidia’s strong results lift Swiss chip suppliers modestly amid mixed market signals

Comet, Inficon and VAT Group gain 1.4%-2.1% after Nvidia’s Q2 revenue surge, but broader semiconductor volatility remains subdued. Analysts cite solid fundamentals for VAT as Citigroup sets a 850-franc target.

Nvidia lifts premarket U.S. stocks; Salesforce surges on outlook; SMI falls
AktienArtikel

Nvidia lifts premarket U.S. stocks; Salesforce surges on outlook; SMI falls

U.S. futures rise as Nvidia’s results fuel AI optimism; Salesforce jumps 10% on raised revenue guidance. Swiss SMI declines 0.9% as heavyweights Nestlé, Novartis and Roche weigh.

UBS flags commodities as inflation hedge amid Middle East risks
RohstoffeArtikel

UBS flags commodities as inflation hedge amid Middle East risks

Strategists recommend broad exposure to energy, metals and agriculture as geopolitical tensions and weather patterns reshape supply. Brent crude near $87, European gas at 65 euros/MWh.

US tech shares rise on Nvidia rally; Swiss SMI falls on heavyweights
AktienArtikel

US tech shares rise on Nvidia rally; Swiss SMI falls on heavyweights

Nasdaq 100 gains 1% as Nvidia soars 7.3% on AI demand; S&P 500 up 0.46%; HP drops 6% on weak outlook; Swiss SMI down 1.2% as heavyweights weigh.

Novartis shares hit record high on multiple sclerosis drug data
AktienArtikel

Novartis shares hit record high on multiple sclerosis drug data

Swiss pharma giant rallies 6.3% after positive late-stage trial results for oral multiple sclerosis drug Remibrutinib, outpacing broader market slump. Analysts flag upside potential but warn of near-term consolidation risks.

Investis reports 6.8% rise in H1 rental income, LTV falls to 27.3%
AktienArtikel

Investis reports 6.8% rise in H1 rental income, LTV falls to 27.3%

Swiss real estate firm posts CHF 41.5 million in rental income for the half-year, while loan-to-value ratio declines to 27.3%. Portfolio value reaches CHF 2.3 billion.

European stocks fall despite Nvidia gains as Jackson Hole looms
AktienArtikel

European stocks fall despite Nvidia gains as Jackson Hole looms

Euro Stoxx 50, FTSE 100 and SMI decline after Nvidia's strong outlook fails to lift broader European equities. Tech sector buoys gains while defensive stocks weigh on Swiss index.

German DAX falls 1.1% as oil prices rise, inflation fears weigh
AktienArtikel

German DAX falls 1.1% as oil prices rise, inflation fears weigh

September opens with losses for Europe's benchmark index as geopolitical tensions lift oil prices and investors reassess rate expectations. Euro Stoxx 50 also declines.

Swiss pharma midcaps Basilea, Siegfried draw value investor interest
AktienArtikel

Swiss pharma midcaps Basilea, Siegfried draw value investor interest

Basilea and Siegfried offer discounted valuations, earnings upgrades and growth prospects as Swiss pharma sector outperformers. Analysts set 38% and 55% upside targets respectively.